Insider Selling: Surrozen (NASDAQ:SRZN) COO Sells 1,566 Shares of Stock

by · The Markets Daily

Surrozen, Inc. (NASDAQ:SRZN – Get Free Report) COO Charles Williams sold 1,566 shares of the company’s stock in a transaction that occurred on Monday, January 5th. The stock was sold at an average price of $19.87, for a total value of $31,116.42. Following the completion of the sale, the chief operating officer owned 12,982 shares of the company’s stock, valued at $257,952.34. This trade represents a 10.76% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Surrozen Stock Up 3.0%

Shares of SRZN stock traded up $0.57 during mid-day trading on Tuesday, hitting $19.67. 78,574 shares of the stock traded hands, compared to its average volume of 85,990. Surrozen, Inc. has a twelve month low of $5.90 and a twelve month high of $24.94. The company’s 50-day simple moving average is $17.64 and its 200-day simple moving average is $13.39.

Surrozen (NASDAQ:SRZN – Get Free Report) last announced its earnings results on Friday, November 7th. The company reported ($3.61) earnings per share for the quarter, missing the consensus estimate of ($1.17) by ($2.44). Surrozen had a negative net margin of 2,909.10% and a negative return on equity of 4,055.04%. The firm had revenue of $0.98 million for the quarter. Equities analysts expect that Surrozen, Inc. will post -8.49 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts recently commented on SRZN shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Surrozen in a research note on Wednesday, October 8th. Lifesci Capital raised Surrozen to a “strong-buy” rating in a report on Thursday, November 13th. Finally, Wall Street Zen raised Surrozen to a “sell” rating in a research note on Friday, November 28th. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Surrozen has an average rating of “Moderate Buy” and a consensus target price of $32.00.

View Our Latest Stock Analysis on SRZN

Hedge Funds Weigh In On Surrozen

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Citadel Advisors LLC raised its stake in Surrozen by 32.8% during the 3rd quarter. Citadel Advisors LLC now owns 13,875 shares of the company’s stock valued at $179,000 after purchasing an additional 3,424 shares during the period. Geode Capital Management LLC grew its holdings in shares of Surrozen by 22.6% during the second quarter. Geode Capital Management LLC now owns 30,963 shares of the company’s stock valued at $277,000 after buying an additional 5,702 shares in the last quarter. Acuta Capital Partners LLC grew its holdings in shares of Surrozen by 5.0% during the third quarter. Acuta Capital Partners LLC now owns 178,415 shares of the company’s stock valued at $2,299,000 after buying an additional 8,415 shares in the last quarter. Stonepine Capital Management LLC raised its position in Surrozen by 7.1% during the second quarter. Stonepine Capital Management LLC now owns 306,029 shares of the company’s stock valued at $2,736,000 after buying an additional 20,247 shares during the period. Finally, Adage Capital Partners GP L.L.C. lifted its stake in Surrozen by 37.1% in the 1st quarter. Adage Capital Partners GP L.L.C. now owns 88,653 shares of the company’s stock worth $1,034,000 after acquiring an additional 24,000 shares in the last quarter. Institutional investors and hedge funds own 66.57% of the company’s stock.

Surrozen Company Profile

(Get Free Report)

Surrozen, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutic antibodies that target the Wnt signaling pathway for applications in tissue repair, regeneration and oncology. Founded in 2012 and headquartered in South San Francisco, California, the company leverages its proprietary SurroBody platform to design bispecific antibody molecules capable of modulating Wnt receptor activity with enhanced tissue specificity.

The SurroBody platform enables the generation of high-affinity, dual-binding antibodies engineered to either activate or inhibit Wnt signaling, a pathway critical to cell proliferation, differentiation and homeostasis.

Featured Stories